glp-1 and kidney disease ICYMI: Agonists Show Promise in Slowing in Lupus Nephritis Recommendations for SGLT2i versus GLP-1

Generic manufacturers that account for 90% of prescriptions face essentially no state tort liability for labeling defects

Massive Bio has onboarded over 160,000+ cancer patients to find their clinical trial Most Recent Article

While the rare risk of medullary thyroid cancer requires a cautious approach for those with a specific family history, these medications offer a potentially transformative path for many who have struggled with weight for years

The results showed that in both IGF-1 treated-group, collagen was significantly increased at day 28 compared to non-IGF-1 supplementation groups (Herchenhan et al., 2015)